ProtoKinetix Successfully Completes Phase 1 Clinical Trials for the Treatment of Type 1 Diabetes in Islet Cell Transplants

Rhea-AI Summary

ProtoKinetix, a clinical-stage biomedical company, announced the successful enrollment completion of its Phase 1 clinical trial for PKX-001 aimed at type 1 diabetes islet cell transplants at the University of Alberta. The trial has achieved primary safety objectives, and patient observation will continue for six months to evaluate secondary objectives. Dr. James Shapiro leads the trial, expressing enthusiasm for the anti-aging glycopeptide molecule's potential benefits. Data collection and analysis will follow the observation period.

Positive

• Successful completion of Phase 1 clinical trial enrollment for PKX-001 aimed at type 1 diabetes.
• Primary safety objectives of the trial have been met.

Negative

• None.

MARIETTA, Ohio--(BUSINESS WIRE)-- ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB: PKTX), a clinical-stage biomedical company, today announced that the University of Alberta has successfully completed Phase 1 clinical trial enrollment for the treatment of type 1 diabetes in islet cell transplants. The molecule, PKX-001 (AAGP®) successfully achieved, to date, the primary safety objectives. The trial is continuing with observation of the latest enrolled patients to monitor secondary objectives over the next 6-months. Following this period of follow-up, all secondary objectives will have been evaluated in all patients, and the data will be collated, analyzed, and reported.

The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet, Liver Transplant and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.

“We are excited to move forward with dose escalation in this exciting trial using this anti-aging glyopeptide molecule AAGP, and eagerly await data on how this might improve and protect islets after transplant. Certainly, at this point the data shows the molecule is safe” - Dr. James Shapiro.

Dr. James Shapiro Bio

To obtain additional information and monitor updates regarding this trial please use the following link: Clinicaltrials.gov – Islet Transplantation Using PKX-001.

About ProtoKinetix, Incorporated

Cautionary Note Regarding Forward-Looking Statements

The information discussed in this press release includes “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements, other than statements of historical facts, included herein concerning, among other things, planned capital expenditures, future cash flows and borrowings, pursuit of potential acquisition opportunities, our financial position, business strategy and other plans and objectives for future operations, are forward looking statements. Although we believe that the expectations reflected in these forward-looking statements are reasonable, they do involve certain assumptions, risks and uncertainties and are not (and should not be considered to be) guarantees of future performance. Refer to our risk factors set forth in our reports filed on Edgar. ProtoKinetix disclaims any obligation to update any forward-looking statement made here.

This press release does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220720005086/en/

Clarence E. Smith

President and Chief Executive Officer

Telephone: 740-434-5041

Email: csmith@protokinetix.com

Twitter: @ProtoKinetix

Source: ProtoKinetix, Incorporated

FAQ

What are the results of the Phase 1 trial for PKTX?

The Phase 1 trial for PKTX has achieved its primary safety objectives, with secondary objectives being observed over the next six months.

Who is leading the PKX-001 clinical trial?

The trial is being led by Dr. James Shapiro from the University of Alberta.

What is PKX-001 and its purpose?

PKX-001 is an anti-aging glycopeptide molecule being tested for its safety and efficacy in type 1 diabetes islet cell transplants.

When will results from the PKX-001 trial be reported?

Results will be collated and analyzed after the six-month observation period of enrolled patients.

What is the significance of the trial for ProtoKinetix (PKTX)?

The trial's success in meeting safety objectives could potentially enhance investor confidence and drive interest in ProtoKinetix's future developments.